Ariel Hurley Sells 3,203 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) Stock

Blueprint Medicines Co. (NASDAQ:BPMC) insider Ariel Hurley sold 3,203 shares of Blueprint Medicines stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $92.62, for a total transaction of $296,661.86. Following the completion of the sale, the insider now directly owns 18,270 shares in the company, valued at $1,692,167.40. This represents a 14.92 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Ariel Hurley also recently made the following trade(s):

• On Monday, January 13th, Ariel Hurley sold 2,250 shares of Blueprint Medicines stock. The stock was sold at an average price of $100.00, for a total transaction of $225,000.00.
• On Thursday, December 12th, Ariel Hurley sold 1,819 shares of Blueprint Medicines stock. The stock was sold at an average price of $93.26, for a total transaction of $169,639.94.

Blueprint Medicines Stock Up 0.6 %

Shares of NASDAQ:BPMC opened at $89.92 on Thursday. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The firm has a market capitalization of $5.75 billion, a PE ratio of -83.26 and a beta of 0.62. The firm’s 50-day moving average is $99.50 and its two-hundred day moving average is $94.34. Blueprint Medicines Co. has a 1 year low of $80.68 and a 1 year high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. Analysts predict that Blueprint Medicines Co. will post -1.28 EPS for the current year.

Institutional Trading of Blueprint Medicines

A number of institutional investors and hedge funds have recently bought and sold shares of BPMC. Mirae Asset Global Investments Co. Ltd. increased its stake in Blueprint Medicines by 22.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,291 shares of the biotechnology company’s stock worth $212,000 after purchasing an additional 422 shares during the period. US Bancorp DE grew its position in shares of Blueprint Medicines by 147.6% during the third quarter. US Bancorp DE now owns 11,971 shares of the biotechnology company’s stock worth $1,107,000 after buying an additional 7,137 shares in the last quarter. M&G PLC acquired a new position in shares of Blueprint Medicines during the third quarter worth about $9,101,000. Covestor Ltd grew its position in shares of Blueprint Medicines by 206.7% during the third quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock worth $55,000 after buying an additional 403 shares in the last quarter. Finally, Entropy Technologies LP acquired a new position in shares of Blueprint Medicines during the third quarter worth about $999,000.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on BPMC shares. JPMorgan Chase & Co. lifted their target price on shares of Blueprint Medicines from $126.00 to $129.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. JMP Securities reiterated a “market outperform” rating and set a $125.00 price target on shares of Blueprint Medicines in a report on Friday, February 14th. Piper Sandler lifted their price target on Blueprint Medicines from $109.00 to $119.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. HC Wainwright reiterated a “buy” rating and set a $135.00 price target on shares of Blueprint Medicines in a report on Friday, February 14th. Finally, Stephens reiterated an “overweight” rating and set a $140.00 price target on shares of Blueprint Medicines in a report on Thursday, January 2nd. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $123.83.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.